IMMUNEERING CORPORATION - CLASS A COMMON STOCK

Immuneering Appoints Harold E. Brakewood as Chief Business Officer

28 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

14 Mar 2023 16:30:00 By Nasdaq GlobeNewswire

Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

06 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity

05 Mar 2023 18:30:00 By Nasdaq GlobeNewswire

Immuneering Announces Participation in March Investor Conferences

28 Feb 2023 08:00:02 By Nasdaq GlobeNewswire

Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

27 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

Immuneering To Present at Guggenheim 2023 Oncology Conference

31 Jan 2023 06:50:00 By Nasdaq GlobeNewswire

Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations

28 Nov 2022 06:50:00 By Nasdaq GlobeNewswire

Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC

10 Nov 2022 09:00:04 By Nasdaq GlobeNewswire

Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights

10 Nov 2022 09:00:02 By Nasdaq GlobeNewswire

Immuneering Announces Participation in November Investor Conferences

03 Nov 2022 06:50:00 By Nasdaq GlobeNewswire

Immuneering Appoints Leah R. Neufeld as Chief People Officer

20 Oct 2022 06:50:00 By Nasdaq GlobeNewswire

Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

05 Oct 2022 08:05:00 By Nasdaq GlobeNewswire

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

30 Sep 2022 06:50:00 By Nasdaq GlobeNewswire

Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

02 Sep 2022 08:09:07 By Nasdaq GlobeNewswire

Immuneering Announces Participation in September Investor Conferences

25 Aug 2022 06:50:00 By Nasdaq GlobeNewswire

Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights 

10 Aug 2022 16:05:01 By Nasdaq GlobeNewswire

Immuneering Announces Participation in William Blair Biotech Focus Conference 2022

06 Jul 2022 06:50:00 By Nasdaq GlobeNewswire

Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104

26 May 2022 17:26:00 By Nasdaq GlobeNewswire

Immuneering Announces Participation in Upcoming Investor Conferences

20 May 2022 06:50:00 By Nasdaq GlobeNewswire